Bayer's Two-Front Growth Strategy: Agrochemical Innovation Meets Pharma's Newest Star

Bayer unveils new ag products, Kerendia sales surge 75%, but glyphosate settlement hearing in September looms over shares.

Bayer is asking investors to look in two directions at once these days. In Iowa, the company is rolling out a wave of crop-science products designed to defend its turf in the competitive agricultural market. In the pharmaceutical division, meanwhile, a kidney and heart medication is quietly emerging as one of the few bright spots in an otherwise mixed operational picture — and the clock is ticking toward a pivotal legal date in September.

The German conglomerate used its Innovation Showcase in Iowa on Wednesday to unveil a suite of new agricultural offerings. Chief among them is the Preceon corn seed system, which the company plans to expand significantly by 2035. While Bayer declined to provide specific hectare targets for Germany or Europe, the system is already in use in Argentina, where 1,000 bags are currently deployed. The company also presented Plenexos, an insecticide that reportedly requires 75 percent less active ingredient than comparable products, alongside Vyconic, a soybean variety with five tolerance traits slated for a 2027 launch in the US and Canada.

Perhaps the most financially significant announcement concerns Icafolin, a herbicide featuring a novel mechanism of action that Bayer believes can generate €750 million in sales potential by 2035. The breadth of these launches underscores how heavily the company is leaning on technological differentiation to hold market share in an intensely competitive agricultural landscape.

Digital Tools and a Faster Breeding Pipeline

Beyond new chemistries and seed lines, Bayer is pushing forward on the digitalization front. The company introduced MagicTrap 2, an upgraded version of its digital pest-monitoring system for rapeseed. The new camera comes equipped with autofocus, flash, and an improved antenna, giving farmers more precise remote monitoring capabilities and, according to Bayer, enabling more targeted pesticide application.

The pace of innovation itself is accelerating. JD Rossouw, cited in the company's materials, notes that Bayer now develops new plant varieties roughly 15 times faster than two decades ago — the process has been compressed from five years down to four months. That speed matters in a market where the global agricultural genetics sector is projected to grow at 6.5 percent annually between 2023 and 2030, reaching $1.5 billion, according to estimates from Fairfield.

The addressable opportunity is substantial, particularly among smaller operations. Some 97 percent of the world's farmers are smallholders cultivating fewer than ten hectares, yet they produce more than half of the food in low- and middle-income countries. While 91 percent of US farmers already use digital tools, the global adoption rate sits at just 65 percent — a gap Bayer clearly views as a growth runway in emerging markets.

Crop Science generated €21.6 billion in revenue in 2025, cementing its role as a cornerstone of the group. The innovations unveiled at the showcase are intended to reinforce that foundation and help Bayer hold its ground against competitors in the crucial North American market.

The Pharma Counterweight

While Crop Science provides scale, the pharmaceutical division is searching for momentum — and Kerendia is emerging as a candidate to deliver it. At the ESC Congress in Munich in late August, Bayer presented a subgroup analysis from the Phase III FIND-CKD trial showing the drug can also benefit patients with hypertensive nephropathy, kidney damage caused by chronic high blood pressure. The finding matters beyond the clinical detail: it broadens the potential indications for a medication that generated €603 million in revenue in the first half of 2026, a 75 percent increase year over year.

That growth rate is striking, though it starts from a relatively modest base. The broader business context is more subdued. In the second quarter of 2026, group revenue grew just 2.2 percent on a currency- and portfolio-adjusted basis to €10.9 billion, while core earnings per share fell 16.7 percent to €0.95, weighed down by a higher tax rate and weaker segment results. Kerendia stands out as one of the few growth stories in a pharma segment that is otherwise performing unevenly.

The central question for investors is whether Kerendia can scale into a meaningful revenue pillar — one capable of offsetting softness elsewhere in pharma and Consumer Health — before the glyphosate legal overhang returns to center stage in September.

A Balance Sheet Bright Spot

Financial flexibility is improving on another front. The capital injection from Apollo Global Management, agreed over the summer, brings €3 billion into the company. As a result, Bayer has revised its expected year-end net financial debt downward from €32–33 billion to €29–30 billion. That breathing room matters as the company funds both its agricultural innovation pipeline and its pharmaceutical ambitions.

The immediate test, however, remains legal rather than commercial. The fairness hearing for final approval of the $7.25 billion glyphosate class-action settlement is scheduled for September 14. Bayer and plaintiffs' attorneys jointly requested the postponement to process opt-out revocation requests following the Supreme Court's decision — a procedural step that underscores how unresolved questions persist even after the Court's favorable preemption ruling in June. A setback at the hearing could quickly overshadow the operational improvements the company has been working to demonstrate.

For now, the bull case rests on a combination: Kerendia sustaining its growth trajectory while additional clinical data support further label expansions, alongside a shrinking debt burden and a crop-science division that continues to deliver. The bear case is equally clear — the drug's growth comes from a small base, core earnings per share are already declining, and the legal calendar could derail the narrative at any moment.

The share price reflects the tension. On Wednesday, Bayer stock edged up 0.2 percent to €48.80, hovering just above its 50-day average of €48.57 — a sign of consolidation after the strong rally of recent months. The stock sits roughly 9.4 percent below its year-to-date high of €53.86, reached on July 3. Whether that gap narrows may depend less on the products unveiled in Iowa and more on what happens in a courtroom in mid-September.